CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant wilms' tumors

Chi Ming Li, Connie E. Kim, Adam Margolin, Meirong Guo, Jimmy Zhu, Jacqueline M. Mason, Terrence W. Hensle, Vundavalli V V S Murty, Paul E. Grundy, Eric R. Fearon, Vivette D'Agati, Jonathan D. Licht, Benjamin Tycko

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Gain-of-function mutations in exon 3 of β-catenin (CTNNB1) are specific for Wilms' tumors that have lost WT1, but 50% of WT1-mutant cases lack such "hot spot" mutations. To ask whether stabilization of β-catenin might be essential after WT1 loss, and to identify downstream target genes, we compared expression profiles in WT1-mutant versus WT1 wild-type Wilms' tumors. Supervised and nonsupervised hierarchical clustering of the expression data separated these two classes of Wilms' tumor. The WT1-mutant tumors overexpressed genes encoding myogenic and other transcription factors (MOX2, LBX1, SIM2), signalling molecules (TGFB2, FST, BMP2A), extracellular Wnt inhibitors (WIF1, SFRP4), and known β-catenin/TCF targets (FST, CSPG2, CMYC). β-Catenin/TCF target genes were overexpressed in the WT1-mutant tumors even in the absence of CTNNB1 exon 3 mutations, and complete sequencing revealed gain-of-function mutations elsewhere in the CTNNB1 gene to some of these tumors, increasing the overall mutation frequency to 75%. Lastly, we identified and validated a novel direct β-catenin target gene, GAD1, among the WT1-mutant signature genes. These data highlight two molecular classes of Wilms' tumor, and indicate strong selection for stabilization of β-catenin in the WT1-mutant class. β-Catenin stabilization can initiate tumorigenesis in other systems, and this mechanism is likely critical in tumor formation after loss of WT1.

Original languageEnglish (US)
Pages (from-to)1943-1953
Number of pages11
JournalAmerican Journal of Pathology
Volume165
Issue number6
StatePublished - Dec 2004
Externally publishedYes

Fingerprint

Catenins
Wilms Tumor
Mutation
Genes
Exons
Neoplasms
Mutation Rate
Transcriptome
Cluster Analysis
Carcinogenesis
Transcription Factors

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Li, C. M., Kim, C. E., Margolin, A., Guo, M., Zhu, J., Mason, J. M., ... Tycko, B. (2004). CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant wilms' tumors. American Journal of Pathology, 165(6), 1943-1953.

CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant wilms' tumors. / Li, Chi Ming; Kim, Connie E.; Margolin, Adam; Guo, Meirong; Zhu, Jimmy; Mason, Jacqueline M.; Hensle, Terrence W.; Murty, Vundavalli V V S; Grundy, Paul E.; Fearon, Eric R.; D'Agati, Vivette; Licht, Jonathan D.; Tycko, Benjamin.

In: American Journal of Pathology, Vol. 165, No. 6, 12.2004, p. 1943-1953.

Research output: Contribution to journalArticle

Li, CM, Kim, CE, Margolin, A, Guo, M, Zhu, J, Mason, JM, Hensle, TW, Murty, VVVS, Grundy, PE, Fearon, ER, D'Agati, V, Licht, JD & Tycko, B 2004, 'CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant wilms' tumors', American Journal of Pathology, vol. 165, no. 6, pp. 1943-1953.
Li, Chi Ming ; Kim, Connie E. ; Margolin, Adam ; Guo, Meirong ; Zhu, Jimmy ; Mason, Jacqueline M. ; Hensle, Terrence W. ; Murty, Vundavalli V V S ; Grundy, Paul E. ; Fearon, Eric R. ; D'Agati, Vivette ; Licht, Jonathan D. ; Tycko, Benjamin. / CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant wilms' tumors. In: American Journal of Pathology. 2004 ; Vol. 165, No. 6. pp. 1943-1953.
@article{9a4d2084b36e4d5b808be2ff5daecef8,
title = "CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant wilms' tumors",
abstract = "Gain-of-function mutations in exon 3 of β-catenin (CTNNB1) are specific for Wilms' tumors that have lost WT1, but 50{\%} of WT1-mutant cases lack such {"}hot spot{"} mutations. To ask whether stabilization of β-catenin might be essential after WT1 loss, and to identify downstream target genes, we compared expression profiles in WT1-mutant versus WT1 wild-type Wilms' tumors. Supervised and nonsupervised hierarchical clustering of the expression data separated these two classes of Wilms' tumor. The WT1-mutant tumors overexpressed genes encoding myogenic and other transcription factors (MOX2, LBX1, SIM2), signalling molecules (TGFB2, FST, BMP2A), extracellular Wnt inhibitors (WIF1, SFRP4), and known β-catenin/TCF targets (FST, CSPG2, CMYC). β-Catenin/TCF target genes were overexpressed in the WT1-mutant tumors even in the absence of CTNNB1 exon 3 mutations, and complete sequencing revealed gain-of-function mutations elsewhere in the CTNNB1 gene to some of these tumors, increasing the overall mutation frequency to 75{\%}. Lastly, we identified and validated a novel direct β-catenin target gene, GAD1, among the WT1-mutant signature genes. These data highlight two molecular classes of Wilms' tumor, and indicate strong selection for stabilization of β-catenin in the WT1-mutant class. β-Catenin stabilization can initiate tumorigenesis in other systems, and this mechanism is likely critical in tumor formation after loss of WT1.",
author = "Li, {Chi Ming} and Kim, {Connie E.} and Adam Margolin and Meirong Guo and Jimmy Zhu and Mason, {Jacqueline M.} and Hensle, {Terrence W.} and Murty, {Vundavalli V V S} and Grundy, {Paul E.} and Fearon, {Eric R.} and Vivette D'Agati and Licht, {Jonathan D.} and Benjamin Tycko",
year = "2004",
month = "12",
language = "English (US)",
volume = "165",
pages = "1943--1953",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - CTNNB1 mutations and overexpression of Wnt/β-catenin target genes in WT1-mutant wilms' tumors

AU - Li, Chi Ming

AU - Kim, Connie E.

AU - Margolin, Adam

AU - Guo, Meirong

AU - Zhu, Jimmy

AU - Mason, Jacqueline M.

AU - Hensle, Terrence W.

AU - Murty, Vundavalli V V S

AU - Grundy, Paul E.

AU - Fearon, Eric R.

AU - D'Agati, Vivette

AU - Licht, Jonathan D.

AU - Tycko, Benjamin

PY - 2004/12

Y1 - 2004/12

N2 - Gain-of-function mutations in exon 3 of β-catenin (CTNNB1) are specific for Wilms' tumors that have lost WT1, but 50% of WT1-mutant cases lack such "hot spot" mutations. To ask whether stabilization of β-catenin might be essential after WT1 loss, and to identify downstream target genes, we compared expression profiles in WT1-mutant versus WT1 wild-type Wilms' tumors. Supervised and nonsupervised hierarchical clustering of the expression data separated these two classes of Wilms' tumor. The WT1-mutant tumors overexpressed genes encoding myogenic and other transcription factors (MOX2, LBX1, SIM2), signalling molecules (TGFB2, FST, BMP2A), extracellular Wnt inhibitors (WIF1, SFRP4), and known β-catenin/TCF targets (FST, CSPG2, CMYC). β-Catenin/TCF target genes were overexpressed in the WT1-mutant tumors even in the absence of CTNNB1 exon 3 mutations, and complete sequencing revealed gain-of-function mutations elsewhere in the CTNNB1 gene to some of these tumors, increasing the overall mutation frequency to 75%. Lastly, we identified and validated a novel direct β-catenin target gene, GAD1, among the WT1-mutant signature genes. These data highlight two molecular classes of Wilms' tumor, and indicate strong selection for stabilization of β-catenin in the WT1-mutant class. β-Catenin stabilization can initiate tumorigenesis in other systems, and this mechanism is likely critical in tumor formation after loss of WT1.

AB - Gain-of-function mutations in exon 3 of β-catenin (CTNNB1) are specific for Wilms' tumors that have lost WT1, but 50% of WT1-mutant cases lack such "hot spot" mutations. To ask whether stabilization of β-catenin might be essential after WT1 loss, and to identify downstream target genes, we compared expression profiles in WT1-mutant versus WT1 wild-type Wilms' tumors. Supervised and nonsupervised hierarchical clustering of the expression data separated these two classes of Wilms' tumor. The WT1-mutant tumors overexpressed genes encoding myogenic and other transcription factors (MOX2, LBX1, SIM2), signalling molecules (TGFB2, FST, BMP2A), extracellular Wnt inhibitors (WIF1, SFRP4), and known β-catenin/TCF targets (FST, CSPG2, CMYC). β-Catenin/TCF target genes were overexpressed in the WT1-mutant tumors even in the absence of CTNNB1 exon 3 mutations, and complete sequencing revealed gain-of-function mutations elsewhere in the CTNNB1 gene to some of these tumors, increasing the overall mutation frequency to 75%. Lastly, we identified and validated a novel direct β-catenin target gene, GAD1, among the WT1-mutant signature genes. These data highlight two molecular classes of Wilms' tumor, and indicate strong selection for stabilization of β-catenin in the WT1-mutant class. β-Catenin stabilization can initiate tumorigenesis in other systems, and this mechanism is likely critical in tumor formation after loss of WT1.

UR - http://www.scopus.com/inward/record.url?scp=9644265525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644265525&partnerID=8YFLogxK

M3 - Article

C2 - 15579438

AN - SCOPUS:9644265525

VL - 165

SP - 1943

EP - 1953

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -